Effectiveness of HIF-PHIs in Treating Renal Anemia in CKD Patients
Author Information
Author(s): Yoshida Yukina, Takata Tomoaki, Taniguchi Sosuke, Kageyama Kana, Fujino Yudai, Hanada Hinako, Mae Yukari, Iyama Takuji, Hikita Katsuya, Isomoto Hajime
Primary Institution: Tottori University
Hypothesis
Can hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs) improve erythropoiesis and long-term outcomes in patients with chronic kidney disease (CKD) compared to erythropoietin-stimulating agents (ESAs)?
Conclusion
HIF-PHIs can serve as an alternative to ESA for managing renal anemia in CKD, improving both hematological parameters and long-term outcomes.
Supporting Evidence
- HIF-PHI and ESA significantly increased hemoglobin levels within 6 months of treatment.
- The HIF-PHI group showed a significant decrease in red cell distribution width, indicating improved erythropoiesis.
- Patients treated with HIF-PHI had a lower incidence of dialysis initiation and mortality during follow-up.
Takeaway
This study shows that a new type of medicine called HIF-PHIs can help people with kidney problems make more red blood cells and feel better over time.
Methodology
A retrospective analysis of laboratory data from 105 CKD patients treated with HIF-PHI or ESA, assessing changes in erythropoiesis and long-term outcomes over a median follow-up of 614 days.
Potential Biases
Potential biases due to the non-randomized nature of the study and exclusion of certain patient groups.
Limitations
The study's retrospective design and small sample size limit the generalizability of the findings.
Participant Demographics
Patients with chronic kidney disease, including those treated with HIF-PHI or ESA, with a mean age of approximately 76 years.
Statistical Information
P-Value
p = 0.042
Confidence Interval
95% confidence interval: 0.091–0.955
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website